Validity and reliability of the Rosacea Area and Severity Index: A novel scoring system for clinical assessment of rosacea severity.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
26
07
2022
accepted:
25
10
2022
pubmed:
5
11
2022
medline:
16
2
2023
entrez:
4
11
2022
Statut:
ppublish
Résumé
Rosacea is a common chronic inflammatory facial skin disorder. Standardized evaluation of the severity and extent of rosacea is important for baseline assessment and treatment effect. The currently used Investigator's Global Assessment (IGA) is unspecific and fails to consider subtypes/phenotypes of rosacea and area involvement. The Rosacea Area and Severity Index (RASI) was developed to give a more nuanced evaluation of rosacea features in four facial skin areas adjusted to the relative importance of each area of the face to obtain an overall severity score. To validate RASI against the IGA and to assess the inter- and intraobserver reliability for RASI. Sixteen dermatologists evaluated photographs of 60 adult patients with rosacea (3 photographs per patient, one from the front and one from each side). IGA and RASI scores were performed for interobserver reliability assessment. To determine intraobserver reliability, 14 dermatologists evaluated 10 other patients twice with at least 1 week interval. The IGA and RASI correlated well (Spearman correlation coefficient (SCC) = 0.75, 95% confidence interval (CI) = 0.72-0.78). Interobserver reliability was moderate for RASI and poor to moderate for IGA. Reliability was strongest for rhinophyma, followed by papules/pustules and erythema, and rather weak for telangiectasia. For area scores, interobserver reliability was strongest for cheeks, followed by nose, chin and forehead. We found a moderate-to-strong intraobserver agreement both for IGA and RASI. We have designed a new practical tool to examine clinical severity of rosacea. RASI proved simple and reliable in scoring clinical severity of rosacea with an agreement comparable to the currently used IGA although RASI will provide a more nuanced view of the current rosacea extent and severity. We suggest that RASI is used in the daily clinical setting as well as in clinical studies assessing the efficacy of rosacea therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Rosacea is a common chronic inflammatory facial skin disorder. Standardized evaluation of the severity and extent of rosacea is important for baseline assessment and treatment effect. The currently used Investigator's Global Assessment (IGA) is unspecific and fails to consider subtypes/phenotypes of rosacea and area involvement. The Rosacea Area and Severity Index (RASI) was developed to give a more nuanced evaluation of rosacea features in four facial skin areas adjusted to the relative importance of each area of the face to obtain an overall severity score.
OBJECTIVES
OBJECTIVE
To validate RASI against the IGA and to assess the inter- and intraobserver reliability for RASI.
METHODS
METHODS
Sixteen dermatologists evaluated photographs of 60 adult patients with rosacea (3 photographs per patient, one from the front and one from each side). IGA and RASI scores were performed for interobserver reliability assessment. To determine intraobserver reliability, 14 dermatologists evaluated 10 other patients twice with at least 1 week interval.
RESULTS
RESULTS
The IGA and RASI correlated well (Spearman correlation coefficient (SCC) = 0.75, 95% confidence interval (CI) = 0.72-0.78). Interobserver reliability was moderate for RASI and poor to moderate for IGA. Reliability was strongest for rhinophyma, followed by papules/pustules and erythema, and rather weak for telangiectasia. For area scores, interobserver reliability was strongest for cheeks, followed by nose, chin and forehead. We found a moderate-to-strong intraobserver agreement both for IGA and RASI.
CONCLUSIONS
CONCLUSIONS
We have designed a new practical tool to examine clinical severity of rosacea. RASI proved simple and reliable in scoring clinical severity of rosacea with an agreement comparable to the currently used IGA although RASI will provide a more nuanced view of the current rosacea extent and severity. We suggest that RASI is used in the daily clinical setting as well as in clinical studies assessing the efficacy of rosacea therapies.
Substances chimiques
Immunoglobulin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-580Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Gether L, Overgaard L, Egeberg A, Thyssen J. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179:282-9.
Moustafa F, Lewallen R, Feldman S. The psychological impact of rosacea and the influence of current management options. J Am Dermatology. 2014;71:973-80.
Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with rosacea have increased risk of depression and anxiety disorders: a Danish Nationwide cohort study. Dermatology. 2016;232:208-13.
Bewley A, Fowler J, Schöfer H, Kerroche N, Rives V. Erythema of rosacea impairs health-related quality of life: results of a meta-analysis. Dermatol Ther. 2016;6:237-47.
Tan J, Almeida L, Bewley A, Cribier B, Dlova NS, Gallo R, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465-71.
Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-7.
Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society expert committee. J Am Acad Dermatol. 2018;78:148-55.
Fredriksson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica. 1978;157:238-44.
Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-8.
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Contact Dermatitis. 2005;152:302-7.
Wienholtz NKF, Christensen CE, Zhang DG, Rechnagel AA, Byrnel HVS, Haugaard JH, et al. Clinical characteristics of combined rosacea and migraine. Front Med (Lausanne). 2022;9:1026447.
Raadt D, Matthijs J, Roel J, Henk AL. A comparison of reliability coefficients for ordinal rating scales. J Classif. 2021;38:519-43.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;2:307-10.
Correlation and regression [online]. BMJ. [cited 2022 Jul 25]. Available from: https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155-63.
Finlay AY, Khan G. Dermatology life quality index. Clin Exp Dermatol. 1994;19:210-6.
Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57:213-21.
Steinhoff M, Harper J, Gieler U, Tan J. Rosacea: beyond the visible. BMJ Hosted Content 2018 [online]. [cited 2022 Jul 25]. Available from: https://hosted.bmj.com/rosaceabeyondthevisible.